EXEL-1-13-19

EXEL – delivered stunning 32% gain since my bullish call in mid November 2018 Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. It has very strong fundamentals. It’s Net Margin is 49%. Return on equity is 49%. However, it is not longer cheap. It is Read more…

Login